Table 3 Clinical characteristics of study subjects at baseline, 2^nd, 5^th and 6^th months of anti-TB treatment period, September 2013- March 2015

Cough

784 (65.1)

79 (72.5)

0.12

166 (14.0)

23 (23.0)

0.02

24 (2.1)

2 (2.2)

1.00*

18 (1.6)

2 (2.2)

0.66*

Fever

933 (78.4)

80 (73.4)

0.34

166 (14.0)

18 (18.0)

0.28

29 (2.5)

2 (2.2)

1.00*

13 (1.1)

1 (1.1)

1.00*

Hemoptysis

228 (18.9)

24 (22.0)

0.43

18 (1.5)

6 (6.0)

0.008

4 (0.3)

-

-

1 (0.1)

-

-

Weight loss

949 (78.8)

94 (86.2)

0.06

86 (7.3)

14 (14.0)

0.02

14 (1.2)

2 (2.2)

0.34*

10 (0.9)

1 (1.1)

0.58*

Poor appetite

922 (76.5)

86 (78.9)

0.57

154 (13.0)

16 (16.0)

0.39

25 (2.2)

2 (2.2)

1.00*

10 (0.9)

-

-

Night sweat

818 (67.9)

75 (68.8)

0.84

121 (10.2)

6 (6.0)

0.17

21 (1.8)

2 (2.2)

0.69*

14 (1.2)

2 (2.2)

0.34*

Dyspnea

587 (48.7)

52 (47.7)

0.84

93 (7.9)

9 (9.0)

0.68

24 (2.1)

2 (2.2)

1.00*

9 (0.8)

2 (2.2)

0.20*

Chest pain

683 (56.7)

64 (58.7)

0.68

108 (9.1)

9 (9.0)

0.96

26 (2.3)

4 (4.3)

0.27*

9 (0.8)

2 (2.2)

0.20*

Fatigue

967 (80.2)

90 (82.6)

0.56

207 (17.5)

29 (29.0)

0.004

46 (4.0)

5 (5.4)

0.42*

21 (1.8)

3 (3.2)

0.42*

BMI (kg/m²)

<18.5

720 (69.5)

59 (54.1)

567 (47.9)

48 (48.0)

424 (36.8)

37 (39.8)

377 (33.2)

33 (35.5)

18.5–24.9

445 (36.9)

44 (40.4)

583 (49.3)

42 (42.0)

686 (59.5)

48 (51.6)

713 (62.8)

51 (54.8)

≥25

31 (2.6)

6 (5.5)

0.13*

33 (2.8)

10 (10.0)

0.002*

42 (3.6)

8 (8.6)

0.05*

46 (4.0)

9 (9.7)

0.04*

Mean (± SD)

18.05 (±2.94)

18.35(±3.72)

0.31

18.95 (±5.79)

21.29 (±20.46)

0.005

19.55 (±3.50)

19.98 (±3.86)

0.26*

19.78 (±2.87)

20.58 (±4.95)

0.02